AXIM® Biotechnologies, Inc. Nutraceutical Division Receives Purchase Order for 50,000 Boxes of the Company’s Proprietary CBD-Based Chewing Gum

NEW YORK, April 23, 2019 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that the nutraceutical division of the Company, which produces and distributes cannabinoid-based lifestyle and wellness products, has received a purchase order for 50,000 boxes of its proprietary cannabidiol (CBD)-based chewing gum from a leading direct-to-consumer company for distribution throughout the United States.